| Dr Hiram Efrain Isaac, MD | |
|
54 Calle Celis Aguilera N, Fajardo, PR 00738-4811 | |
| (939) 465-1196 | |
| Not Available |
| Full Name | Dr Hiram Efrain Isaac |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology - Pain Medicine |
| Location | 54 Calle Celis Aguilera N, Fajardo, Puerto Rico |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1114311131 | NPI | - | NPPES |
| Entity Name | Hospitalist Medical Services Psc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1841797743 PECOS PAC ID: 3476833401 Enrollment ID: O20161209000935 |
News Archive
DaVita Inc., a leading provider of kidney care services for those diagnosed with chronic kidney disease (CKD), announced today that on May 28, 2010, it received a subpoena from the Dallas office of the Department of Health and Human Services, Office of Inspector General (OIG). The subpoena relates to a civil investigation that was previously disclosed by the company during its earnings call on April 27, 2010, and in its quarterly report on form 10-Q for the period ended March 31, 2010.
Proteus Digital Health, Inc. announced today that the U.S. Food and Drug Administration has cleared its ingestible sensor for marketing as a medical device. The ingestible sensor (formally referred to as the Ingestion Event Marker or IEM) is part of the Proteus digital health feedback system, an integrated, end-to-end personal health management system that is designed to help improve patients' health habits and connections to caregivers.
Sixteen million family members in the US are caregivers for the more than 6 million people living with Alzheimer's Disease and Related Dementias (ADRD).
Mayo Clinic today announced that Mayo Medical Laboratories has signed an agreement with A&G Pharmaceutical, Inc. and will receive a non-exclusive license to certain patent rights and proprietary antibody reagents for the detection and measurement of progranulin in blood.
Researchers from the La Jolla Institute for Allergy & Immunology have joined forces with the Dana-Farber Cancer Institute in Boston and Washington University in St. Louis to investigate a potential new therapy for sickle cell disease, a severe and chronic illness affecting more than 70,000 Americans and several million people worldwide.
› Verified 9 days ago
| Entity Name | Healing Waters Centro Para El Manejo Del Dolor Y Salud Familiar |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1710689856 PECOS PAC ID: 9335505403 Enrollment ID: O20230515003041 |
News Archive
DaVita Inc., a leading provider of kidney care services for those diagnosed with chronic kidney disease (CKD), announced today that on May 28, 2010, it received a subpoena from the Dallas office of the Department of Health and Human Services, Office of Inspector General (OIG). The subpoena relates to a civil investigation that was previously disclosed by the company during its earnings call on April 27, 2010, and in its quarterly report on form 10-Q for the period ended March 31, 2010.
Proteus Digital Health, Inc. announced today that the U.S. Food and Drug Administration has cleared its ingestible sensor for marketing as a medical device. The ingestible sensor (formally referred to as the Ingestion Event Marker or IEM) is part of the Proteus digital health feedback system, an integrated, end-to-end personal health management system that is designed to help improve patients' health habits and connections to caregivers.
Sixteen million family members in the US are caregivers for the more than 6 million people living with Alzheimer's Disease and Related Dementias (ADRD).
Mayo Clinic today announced that Mayo Medical Laboratories has signed an agreement with A&G Pharmaceutical, Inc. and will receive a non-exclusive license to certain patent rights and proprietary antibody reagents for the detection and measurement of progranulin in blood.
Researchers from the La Jolla Institute for Allergy & Immunology have joined forces with the Dana-Farber Cancer Institute in Boston and Washington University in St. Louis to investigate a potential new therapy for sickle cell disease, a severe and chronic illness affecting more than 70,000 Americans and several million people worldwide.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Hiram Efrain Isaac, MD 54 Calle Celis Aguilera N, Fajardo, PR 00738-4811 Ph: (939) 465-1196 | Dr Hiram Efrain Isaac, MD 54 Calle Celis Aguilera N, Fajardo, PR 00738-4811 Ph: (939) 465-1196 |
News Archive
DaVita Inc., a leading provider of kidney care services for those diagnosed with chronic kidney disease (CKD), announced today that on May 28, 2010, it received a subpoena from the Dallas office of the Department of Health and Human Services, Office of Inspector General (OIG). The subpoena relates to a civil investigation that was previously disclosed by the company during its earnings call on April 27, 2010, and in its quarterly report on form 10-Q for the period ended March 31, 2010.
Proteus Digital Health, Inc. announced today that the U.S. Food and Drug Administration has cleared its ingestible sensor for marketing as a medical device. The ingestible sensor (formally referred to as the Ingestion Event Marker or IEM) is part of the Proteus digital health feedback system, an integrated, end-to-end personal health management system that is designed to help improve patients' health habits and connections to caregivers.
Sixteen million family members in the US are caregivers for the more than 6 million people living with Alzheimer's Disease and Related Dementias (ADRD).
Mayo Clinic today announced that Mayo Medical Laboratories has signed an agreement with A&G Pharmaceutical, Inc. and will receive a non-exclusive license to certain patent rights and proprietary antibody reagents for the detection and measurement of progranulin in blood.
Researchers from the La Jolla Institute for Allergy & Immunology have joined forces with the Dana-Farber Cancer Institute in Boston and Washington University in St. Louis to investigate a potential new therapy for sickle cell disease, a severe and chronic illness affecting more than 70,000 Americans and several million people worldwide.
› Verified 9 days ago
Dr. Manuel A Cabrera Diaz, M.D. Anesthesiology Medicare: Medicare Enrolled Practice Location: Ave. General Valero Km. 2, Fajardo, PR 00738 Phone: 787-655-0505 Fax: 787-655-5021 |